Today's Trend
ProKidney Corp. (NASDAQ: PROK) is under pressure as investors weigh renewed concerns about its cash runway, clinical execution, and continued operating losses. Shares are trading near their 12-month low and below both their 50-day and 200-day moving averages, indicating weak market momentum.
- HC Wainwright maintained a Buy rating and a $12 price target, while modestly improving its fourth-quarter 2026 EPS forecast to a loss of $0.11 from a loss of $0.13. This bullish valuation view provides some potential upside if ProKidney’s clinical program succeeds. FY2030 EPS Estimates for ProKidney Reduced by HC Wainwright
- Morgan Stanley initiated or reiterated a Hold rating on ProKidney, signaling limited conviction in the near-term risk-reward balance and adding to the cautious analyst backdrop. ProKidney Receives a Hold from Morgan Stanley
- HC Wainwright lowered its EPS forecasts for 2026 through 2029, including estimates of losses of $0.52, $0.56, $0.55, and $0.39, respectively. Although the firm remains bullish, the revisions point to higher expected losses and a slower path to profitability.
- A bearish analysis argued that ProKidney’s lead therapy, rilparencel, has produced weak and potentially confounded Phase 2 results. The pivotal Phase 3 PROACT data expected in 2027 is described as a “do-or-die” catalyst, while the company’s roughly $181.6 million cash balance and high cash burn may fund operations only into mid-2027. This raises dilution and going-concern risks before the key data readout. ProKidney Do-Or-Die Phase 3 Meets a Dwindling Balance Sheet
Overall, the stock’s decline appears driven more by financing and clinical-trial risk than by a single new corporate announcement. Investors are likely awaiting PROACT results while evaluating whether ProKidney can avoid raising additional capital before reaching that milestone.